Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Confirmation of the mantle-cell lymphoma International Prognostic Index in randomized trials of the European Mantle-Cell Lymphoma Network

E. Hoster, W. Klapper, O. Hermine, HC. Kluin-Nelemans, J. Walewski, A. van Hoof, M. Trneny, CH. Geisler, F. Di Raimondo, M. Szymczyk, S. Stilgenbauer, C. Thieblemont, M. Hallek, R. Forstpointner, C. Pott, V. Ribrag, J. Doorduijn, W. Hiddemann,...

. 2014 ; 32 (13) : 1338-46.

Language English Country United States

Document type Journal Article, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc14063669

PURPOSE: Mantle-cell lymphoma (MCL) is a distinct B-cell lymphoma associated with poor outcome. In 2008, the MCL International Prognostic Index (MIPI) was developed as the first prognostic stratification tool specifically directed to patients with MCL. External validation was planned to be performed on the cohort of the two recently completed randomized trials of the European MCL Network. PATIENTS AND METHODS: Data of 958 patients with MCL (median age, 65 years; range, 32 to 87 years) treated upfront in the trials MCL Younger or MCL Elderly were pooled to assess the prognostic value of MIPI with respect to overall survival (OS) and time to treatment failure (TTF). RESULTS: Five-year OS rates in MIPI low, intermediate, and high-risk groups were 83%, 63%, and 34%, respectively. The hazard ratios for OS of intermediate versus low and high versus intermediate risk patients were 2.1 (95% CI, 1.5 to 2.9) and 2.6 (2.0 to 3.3), respectively. MIPI was similarly prognostic for TTF. All four clinical baseline characteristics constituting the MIPI, age, performance status, lactate dehydrogenase level, and WBC count, were confirmed as independent prognostic factors for OS and TTF. The validity of MIPI was independent of trial cohort and treatment strategy. CONCLUSION: MIPI was prospectively validated in a large MCL patient cohort homogenously treated according to recognized standards. As reflected in current guidelines, MIPI represents a generally applicable prognostic tool to be used in research as well as in clinical routine, and it can help to develop risk-adapted treatment strategies to further improve clinical outcome in MCL.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc14063669
003      
CZ-PrNML
005      
20140709122643.0
007      
ta
008      
140704s2014 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1200/JCO.2013.52.2466 $2 doi
035    __
$a (PubMed)24687837
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Hoster, Eva $u Eva Hoster, Roswitha Forstpointner, Wolfgang Hiddemann, Martin H. Dreyling, and Michael Unterhalt, University Hospital Munich; Eva Hoster, University of Munich, Munich; Wolfram Klapper, University of Kiel; Christiane Pott, University Hospital Schleswig-Holstein, Kiel; Michael Hallek, Universität Köln, Köln; Stephan Stilgenbauer, University of Ulm, Ulm, Germany; Olivier Hermine, University Paris Descartes and Université Sorbonne Paris Cité; Catherine Thieblemont, Hôpital Saint Louis, Paris; Vincent Ribrag, Institut Gustave Roussy, Villejuif, France; Hanneke C. Kluin-Nelemans, University of Groningen, Groningen; Jeanette Doorduijn, Erasmus MC Cancer Institute, Rotterdam, the Netherlands; Jan Walewski and Michal Szymczyk, Maria Sklodowska-Curie Memorial Institute, Warsaw, Poland; Achiel van Hoof, A. Z. Sint Jan AV, Brugge, Belgium; Marek Trneny, Charles University General Hospital, Prague, Czech Republic; Christian H. Geisler, Rigshospitalet, Copenhagen, Denmark; and Francesco Di Raimondo, University of Catania, Italy.
245    10
$a Confirmation of the mantle-cell lymphoma International Prognostic Index in randomized trials of the European Mantle-Cell Lymphoma Network / $c E. Hoster, W. Klapper, O. Hermine, HC. Kluin-Nelemans, J. Walewski, A. van Hoof, M. Trneny, CH. Geisler, F. Di Raimondo, M. Szymczyk, S. Stilgenbauer, C. Thieblemont, M. Hallek, R. Forstpointner, C. Pott, V. Ribrag, J. Doorduijn, W. Hiddemann, MH. Dreyling, M. Unterhalt,
520    9_
$a PURPOSE: Mantle-cell lymphoma (MCL) is a distinct B-cell lymphoma associated with poor outcome. In 2008, the MCL International Prognostic Index (MIPI) was developed as the first prognostic stratification tool specifically directed to patients with MCL. External validation was planned to be performed on the cohort of the two recently completed randomized trials of the European MCL Network. PATIENTS AND METHODS: Data of 958 patients with MCL (median age, 65 years; range, 32 to 87 years) treated upfront in the trials MCL Younger or MCL Elderly were pooled to assess the prognostic value of MIPI with respect to overall survival (OS) and time to treatment failure (TTF). RESULTS: Five-year OS rates in MIPI low, intermediate, and high-risk groups were 83%, 63%, and 34%, respectively. The hazard ratios for OS of intermediate versus low and high versus intermediate risk patients were 2.1 (95% CI, 1.5 to 2.9) and 2.6 (2.0 to 3.3), respectively. MIPI was similarly prognostic for TTF. All four clinical baseline characteristics constituting the MIPI, age, performance status, lactate dehydrogenase level, and WBC count, were confirmed as independent prognostic factors for OS and TTF. The validity of MIPI was independent of trial cohort and treatment strategy. CONCLUSION: MIPI was prospectively validated in a large MCL patient cohort homogenously treated according to recognized standards. As reflected in current guidelines, MIPI represents a generally applicable prognostic tool to be used in research as well as in clinical routine, and it can help to develop risk-adapted treatment strategies to further improve clinical outcome in MCL.
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a myší monoklonální protilátky $x aplikace a dávkování $7 D058846
650    _2
$a protokoly protinádorové kombinované chemoterapie $x aplikace a dávkování $x terapeutické užití $7 D000971
650    _2
$a chemoradioterapie $7 D059248
650    _2
$a cisplatina $x aplikace a dávkování $7 D002945
650    _2
$a kohortové studie $7 D015331
650    _2
$a cyklofosfamid $x aplikace a dávkování $7 D003520
650    _2
$a cytarabin $x aplikace a dávkování $7 D003561
650    _2
$a dexamethason $x aplikace a dávkování $7 D003907
650    _2
$a doxorubicin $x aplikace a dávkování $7 D004317
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a lymfom z plášťových buněk $x diagnóza $x patologie $x terapie $7 D020522
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a multicentrické studie jako téma $7 D015337
650    _2
$a staging nádorů $7 D009367
650    _2
$a transplantace periferních kmenových buněk $x metody $7 D036102
650    _2
$a prednison $x aplikace a dávkování $7 D011241
650    _2
$a prognóza $7 D011379
650    _2
$a proporcionální rizikové modely $7 D016016
650    _2
$a randomizované kontrolované studie jako téma $x metody $7 D016032
650    _2
$a vinkristin $x aplikace a dávkování $7 D014750
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Klapper, Wolfram
700    1_
$a Hermine, Olivier
700    1_
$a Kluin-Nelemans, Hanneke C
700    1_
$a Walewski, Jan
700    1_
$a van Hoof, Achiel
700    1_
$a Trneny, Marek
700    1_
$a Geisler, Christian H
700    1_
$a Di Raimondo, Francesco
700    1_
$a Szymczyk, Michal
700    1_
$a Stilgenbauer, Stephan
700    1_
$a Thieblemont, Catherine
700    1_
$a Hallek, Michael
700    1_
$a Forstpointner, Roswitha
700    1_
$a Pott, Christiane
700    1_
$a Ribrag, Vincent
700    1_
$a Doorduijn, Jeanette
700    1_
$a Hiddemann, Wolfgang
700    1_
$a Dreyling, Martin H
700    1_
$a Unterhalt, Michael
773    0_
$w MED00002596 $t Journal of clinical oncology : official journal of the American Society of Clinical Oncology $x 1527-7755 $g Roč. 32, č. 13 (2014), s. 1338-46
856    41
$u https://pubmed.ncbi.nlm.nih.gov/24687837 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20140704 $b ABA008
991    __
$a 20140709122934 $b ABA008
999    __
$a ok $b bmc $g 1031153 $s 862401
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2014 $b 32 $c 13 $d 1338-46 $i 1527-7755 $m Journal of clinical oncology $n J. clin. Oncol. $x MED00002596
LZP    __
$a Pubmed-20140704

Find record

Citation metrics

Archiving options